US Stock MarketDetailed Quotes
GUTS Fractyl Health
- 1.800
- -0.010-0.55%
Close Jan 17 16:00 ET
- 1.800
- 0.0000.00%
Post 20:01 ET
86.58MMarket Cap-1.26P/E (TTM)
1.870High1.770Low236.91KVolume1.820Open1.810Pre Close432.30KTurnover1.37%Turnover RatioLossP/E (Static)48.10MShares14.50052wk High1.72P/B31.20MFloat Cap1.74052wk Low--Dividend TTM17.33MShs Float14.500Historical High--Div YieldTTM5.53%Amplitude1.740Historical Low1.824Avg Price1Lot Size
Fractyl Health Stock Forum
Sign in to post a comment
$Fractyl Health (GUTS.US)$
stay away from this app alert
stay away from this app alert
1
1
$Fractyl Health (GUTS.US)$
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Monday, 13th January at 7:00 am
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and anticipa...
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Monday, 13th January at 7:00 am
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and anticipa...
$Fractyl Health (GUTS.US)$
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and rout...
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and rout...
$Fractyl Health (GUTS.US)$ BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease...
1
2
$Fractyl Health (GUTS.US)$ Fractyl Health: Results Show Sustained Maintenance of Weight Loss, Blood Sugar Levels at Week 13 in Dio Mice Given Rjva-001 & Continuing High Fat Diet
1
$Fractyl Health (GUTS.US)$
Oral Presentation
Title: Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
Presentation Date & Time: Tuesday, November 5, 2024, 10:45 am - 11:00 am (CDT)
Location: Henry B. Gonzalez Convention Center, Room 007
Poster Presentation
Title: Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
Presentation Date & Time: Sunday, November 3, 2024,...
Oral Presentation
Title: Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
Presentation Date & Time: Tuesday, November 5, 2024, 10:45 am - 11:00 am (CDT)
Location: Henry B. Gonzalez Convention Center, Room 007
Poster Presentation
Title: Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
Presentation Date & Time: Sunday, November 3, 2024,...
$Fractyl Health (GUTS.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$ $Oklo Inc (OKLO.US)$ $Revance Therapeutics (RVNC.US)$ $PROCEPT BioRobotics (PRCT.US)$ $Atlas Lithium (ATLX.US)$ $EyePoint Pharmaceuticals (EYPT.US)$ $Porch Group (PRCH.US)$ $Top Wealth Group Holding (TWG.US)$ $Global Mofy AI (GMM.US)$ $Monte Rosa Therapeutics (GLUE.US)$ $Evoke Pharma (EVOK.US)$ $Greenlane (GNLN.US)$ $Autonomix Medical (AMIX.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊
📊⚡️📊
11
6
$Fractyl Health (GUTS.US)$ Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
2 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintena...
2 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintena...
3
$Fractyl Health (GUTS.US)$ Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure
Globe Newswire 8-Aug-2024
Globe Newswire 8-Aug-2024
2
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
73962589 : 100 % right